SIGA Technologies (SIGA) Margin Compression Challenges Bullish Narratives After FY 2025 Results

SIGA Technologies (SIGA) has just wrapped up FY 2025 with a mixed earnings print, as fourth quarter revenue came in at about US$3.8 million and basic EPS landed at a loss of US$0.08, while the trailing 12 month figures show total revenue of roughly US$94.6 million and basic EPS of US$0.33. The company has seen quarterly revenue move from US$81.5 million in Q4 2024 to US$81.1 million in Q2 2025 before easing back to US$3.8 million in Q4 2025, with EPS shifting from US$0.64 in Q4 2024 to US$0.50 in Q2 2025 and then into the red at the latest quarter, leaving investors focused on what this means for margins and the durability of recent profitability.

See our full analysis for SIGA Technologies.

With the numbers on the table, the next step is to see how this earnings profile lines up against the widely shared stories about SIGA, highlighting where the usual narratives around growth, quality and risk either hold up or start to crack.

Curious how numbers become stories that shape markets? Explore Community Narratives

NasdaqGM:SIGA Earnings & Revenue History as at Mar 2026
NasdaqGM:SIGA Earnings & Revenue History as at Mar 2026
Advertisement

Net Margin Slips From 42.7% To 24.6%

  • Over the last 12 months, net profit margin sat at 24.6%, compared with 42.7% the year before, while trailing 12 month earnings moved from US$59.2 million a year ago to US$23.3 million now.
  • What stands out for a bearish narrative that focuses on worsening profitability is that margins and earnings have both weakened over the year. At the same time, trailing 12 month revenue of about US$94.6 million and five year earnings growth of 2.7% a year mean the business is still producing profit overall, which partly offsets the concern about the recent drop in margin.
    • Critics highlight that quarterly net income swung from US$45.8 million in Q4 2024 to a loss of US$5.4 million in Q4 2025, which lines up with the margin compression story.
    • At the same time, the trailing 12 month net income of US$23.3 million and positive five year growth rate show the earnings picture is not purely about recent losses.

Lumpy Revenue, From US$81.5m To US$3.8m

  • Over the last six reported quarters, revenue has ranged from about US$81.5 million in Q4 2024 and US$81.1 million in Q2 2025 down to US$3.8 million in Q4 2025, with trailing 12 month revenue at roughly US$94.6 million.
  • Bears often worry that such swings make the business hard to rely on. Yet the trailing 12 month profit of US$23.3 million and basic EPS of US$0.33 over that period show that even with low revenue in the latest quarter, the last year as a whole remained profitable.
    • Quarterly net income moved from US$35.5 million in Q2 2025 to a loss of US$6.4 million in Q3 2025 and a loss of US$5.4 million in Q4 2025, so the weak finish to the year contrasts with earlier profitability.
    • That contrast between strong quarters and recent losses is exactly what beginners should watch, because it highlights how much the business can depend on a few high revenue periods.

P/E Of 16.8x And 58% DCF Gap

  • The trailing P/E of 16.8x sits below the US Pharmaceuticals industry average of 18x and the peer average of 43.5x, while the current share price of about US$5.48 is roughly 58% below a DCF fair value of about US$13.09.
  • Supporters of a bullish view point out that the combination of a lower P/E than both industry and peers, plus a market price around US$5.48 compared with a DCF fair value of about US$13.09, heavily supports the idea that the stock looks inexpensive even after a year where earnings growth was negative.
    • Backing that up, trailing 12 month earnings of US$23.3 million and a five year earnings growth rate of 2.7% a year sit alongside a classification of earnings quality as high over the period.
    • What may surprise you is that this valuation picture comes despite margin compression from 42.7% to 24.6%, so the numbers are not relying on peak profitability to look comparatively cheap.

Curious how this mix of weaker margins, lumpy revenue and seemingly low P/E fits together into a bigger story for SIGA Technologies? 📊 Read the what the Community is saying about SIGA Technologies.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on SIGA Technologies's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Seeing both pressure on margins and a case for value, it is worth checking the underlying data yourself and not relying on a single angle. You can weigh up the balance of concerns and potential upsides by reviewing the 1 key reward and 1 important warning sign that other investors are focused on.

Explore Alternatives

With margins slipping from 42.7% to 24.6% and revenue falling sharply from US$81.5 million to US$3.8 million, SIGA appears exposed to lumpy earnings.

If that concentration risk makes you uneasy, take a few minutes to scan our 67 resilient stocks with low risk scores that highlights steadier businesses with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGM:SIGA

SIGA Technologies

A commercial-stage pharmaceutical company, focuses on the health security market in the United States.

Flawless balance sheet with high growth potential.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
67 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
185 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
71 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0